(Q38458846)

3 September 2017

1 reference

title

Targeting interferons in systemic lupus erythematosus: current and future prospects (English)

1 reference

systemic lupus erythematosus

3 September 2017

1 reference

1 reference

4

Zahir Amoura

1 reference

3 September 2017

Alexis Mathian

1

1 reference

3 September 2017

Miguel Hie

series ordinal

2

1 reference

3 September 2017

Fleur Cohen-Aubart

series ordinal

3

1 reference

3 September 2017

1 May 2015

1 reference

3 September 2017

1 reference

3 September 2017

75

1 reference

3 September 2017

8

1 reference

3 September 2017

835-846

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-015-0394-x

3 September 2017

0 references

cites work

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Mortality in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Differential expression of human interferon genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Rigid interferon-alpha subtype responses of human plasmacytoid dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Type I interferons (alpha/beta) in immunity and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Interferon alpha as a primary pathogenic factor in human lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Cytokines as therapeutic targets in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

The type I interferon system in the development of lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Type I interferon blockade in systemic lupus erythematosus: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Anti-interferon alpha treatment in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-gamma targeting gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Immune Interferon in the Circulation of Patients with Autoimmune Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Interferon-induced 2'-5' adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Possible involvement of interferon alfa in the pathogenesis of fever in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Type I interferon correlates with serological and clinical manifestations of SLE

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Deficiency of the type I interferon receptor protects mice from experimental lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Systemic IFN-alpha drives kidney nephritis in B6.Sle123 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Interferon-α induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZB×NZW)F1 mice but not in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Active immunisation of human interferon α transgenic mice with a human interferon α Kinoid induces antibodies that neutralise interferon α in sera from patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

TLR9 independent interferon α production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

The nature of the principal type 1 interferon-producing cells in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

IFN-gamma transgenic mice: clues to the pathogenesis of systemic lupus erythematosus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Interferons, immunity and cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Novel evidence-based systemic lupus erythematosus responder index

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Combined oral contraceptives in women with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0394-X

Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice

21 January 2018

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis

1 reference

12 December 2020

JAK2 inhibition in murine systemic lupus erythematosus

1 reference

12 December 2020

Immunomodulation of murine experimental SLE-like disease by interferon-gamma

1 reference

12 December 2020

Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon

1 reference

12 December 2020

Gene therapy of autoimmune diseases with vectors encoding regulatory cytokines or inflammatory cytokine inhibitors

1 reference

12 December 2020

Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus

1 reference

12 December 2020

MX homologous protein in mononuclear cells from patients with systemic lupus erythematosus.

1 reference

12 December 2020

Type I interferon subtypes produced by human peripheral mononuclear cells from one normal donor stimulated by viral and non-viral inducing factors

1 reference

12 December 2020

Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis

1 reference

12 December 2020

Interferon expression in the pancreases of patients with type I diabetes

1 reference

12 December 2020

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

1 reference

12 December 2020

Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus

1 reference

12 December 2020

The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.

1 reference

12 December 2020

Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms

1 reference

12 December 2020

Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors

1 reference

12 December 2020

Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells

1 reference

12 December 2020

Systemic lupus erythematosus disease activity index 2000

1 reference

12 December 2020

Interferon-γ and systemic autoimmunity

1 reference

12 December 2020

Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE

1 reference

12 December 2020

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

1 reference

12 December 2020

Immunomodulatory functions of type I interferons

1 reference

12 December 2020

Expression of the markers BDCA-2 and BDCA-4 and production of interferon-alpha by plasmacytoid dendritic cells in systemic lupus erythematosus

1 reference

12 December 2020

Activation of natural interferon-alpha producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines

1 reference

12 December 2020

IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice

1 reference

12 December 2020

Bcl-2 Antagonists Kill Plasmacytoid Dendritic Cells From Lupus-Prone Mice and Dampen Interferon-α Production

1 reference

12 December 2020

Serum interferon levels in patients with systemic lupus erythematosus

1 reference

12 December 2020

Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus

1 reference

12 December 2020

IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice

1 reference

12 December 2020

10.1007/S40265-015-0394-X

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

0 references

1 reference